On Friday, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), lost -0.55% to $28.87.
Celldex Therapeutics, presented positive results from the Company’s randomized, double-blind Phase 2 study of RINTEGA(R) (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The primary endpoint of the study, progression-free survival at six months (PFS6) was met, and a clear advantage was demonstrated across multiple, clinically important endpoints counting overall survival (OS), long-term progression-free survival, objective response rate (ORR) and need for steroids. The data were presented in an oral presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, in addition to the lead investigator of the ReACT study. A webcast/conference call will be held Monday, June 1, 2015 at 8:00 a.m. ET to talk about the results; details are offered below.
RINTEGA is an investigational EGFRvIII specific therapeutic vaccine. Patients with glioblastoma that express the EGFRvIII mutation typically have a worse prognosis than the overall glioblastoma population, counting poor long-term survival.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States.
Shares of Puma Biotechnology Inc (NYSE:PBYI), declined - 2.30% to $ 195.45, during its last trading session.
Puma Biotechnology, declared that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m. EDT on Wednesday, June 3, at the Jefferies 2015 Healthcare Conference.
A live webcast of the presentation will be accessible on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and accessible for 30 days.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer.
At the end of Friday’s trade, Shares of Companhia de Saneamento Basico (ADR) (NYSE:SBS), lost - 1.69% to $ 5.81.
Companhia de Saneamento Basico, declared its 1Q15 results.
In 1Q15, net operating revenue, counting construction revenue, reached R$ 2.5 billion; an 11.6% decrease contrast to 1Q14.
Costs and expenses, counting construction costs, totaled R$ 1.4 billion, down by 32.9% contrast to R$ 2.0 billion recorded in 1Q14. Not taking into account the R$ 696.3 million reimbursement from the Sao Paulo state government, costs and expenses raised R$ 25.8 million or 1.3%.
Adjusted EBIT, in the amount of R$ 1.1 billion, grew 46.1% from R$ 755.6 million recorded in the same quarter of the previous year.
Companhia de Saneamento Basico do Estado de Sao Paulo SABESP provides basic and environmental sanitation services; and supplies treated water on a wholesale basis to residential, commercial, industrial, and governmental customers in the state of Sao Paulo.
Finally, Service Corporation International (NYSE:SCI), ended its last trade with 0.24% gain, and close at $ 29.06.
In the largest donation in the company’s history, Service Corporation International (SCI) and its associates are donating $1,093,961 to the United Way of Greater Houston as the 2014 giving campaign comes to a close.
Since 1988, SCI and its Houston Associates have assisted support families and individuals throughout the Greater Houston area by raising and donating more than $7.4 million to the United Way. The funds that have been raised assist the United Way of Greater Houston fulfill their mission of improving lives and building a stronger community.
Service Corporation International, together with its auxiliaries, provides deathcare products and services in the United States and Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
